{"id":"opc-262","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting S1PR1, OPC-262 is expected to reduce the number of lymphocytes in the blood and lymphoid tissues, thereby exerting anti-inflammatory effects. This mechanism is thought to be beneficial in the treatment of autoimmune diseases such as multiple sclerosis.","oneSentence":"OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:26.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00857558","phase":"PHASE2","title":"A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-01","conditions":"Diabetes, Type 2","enrollment":350},{"nctId":"NCT00997282","phase":"PHASE2, PHASE3","title":"A Study of OPC-262 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-09","conditions":"Diabetes Type 2","enrollment":255},{"nctId":"NCT01046318","phase":"PHASE3","title":"A Study of OPC-262 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-11","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT01634282","phase":"PHASE3","title":"Along-term Study of OPC-262 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-08","conditions":"Diabetes, Type 2","enrollment":222},{"nctId":"NCT01193179","phase":"PHASE3","title":"A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-07","conditions":"Diabetes, Type 2","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OPC-262","genericName":"OPC-262","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}